Largest borrow rate increases among liquid names » 08:4508/1008/10/20
MVIS, DGLY, XSPA, NBRV, TAN, AMTD, QGEN, LILAK, OIH, UPRO
Latest data shows the…
Wells Fargo to hold a virtual forum » 08:3108/1008/10/20
ACIW, BKI, CATM, CDLX, DNB, EEFT, EFX, FDS, FICO, FIS, FORR, IBM, INFO, IT, J, MANT, MCO, NLSN, PBI, PSN, PYPL, SPGI, TRU, WEC, WEX, WFC, WU, ZIP
Virtual 5th Annual…
Revolution Medicines reports Q2 EPS (46c), consensus (35c) » 07:4308/1008/10/20
Reports Q revenue $10M,…
Reports Q revenue $10M, consensus $13.36M. "Revolution Medicines continues pursuit of its ambitious R&D strategy on behalf of cancer patients with RAS-addicted tumors. Our cohesive pipeline focuses on multiple key nodes within RAS signaling and interconnected pathways to enable combination treatment approaches that may be needed to maximize patient benefit in these vexing cancers," said Mark A. Goldsmith, M.D., Ph.D., chief executive officer and chairman of Revolution Medicines."In the second quarter, we made broad progress across our portfolio of targeted inhibitors. RMC-4630, our clinical stage inhibitor of SHP2 and a potential backbone in combination treatments, showed further evidence of clinical activity against genetically-defined tumors. Importantly, combination studies of RMC-4630 with the KRASG12C inhibitor, AMG 510, and the checkpoint inhibitor, Keytruda, were initiated. We also introduced a potential role for our second clinical candidate, RMC-5552, in combination therapy against cancers carrying dual RAS/mTOR pathway mutations. Further, we made substantial progress toward nomination of a first development candidate from our innovative family of targeted RAS inhibitors. Finally, just after the quarter, we completed a successful first follow-on financing, further strengthening our financial position to enable the continued advancement of our deep R&D pipeline."
Pacira price target raised to $70 from $68 at H.C. Wainwright » 06:2008/1008/10/20
H.C. Wainwright analyst…
Chembio Diagnostics reports Q2 EPS (42c), consensus (39c) » 16:4708/0608/06/20
Reports Q2 revenue $5.1M,…
Reports Q2 revenue $5.1M, consensus $6.88M "Despite challenging circumstances in the quarter, we are optimistic that our scientific expertise and platform flexibility will allow us to develop additional high quality, easy to use point-of-care COVID-19 tests that will contribute to the decentralization of testing. Central laboratories are currently facing extreme testing volumes that are creating delays in returning results to patients and our technology can contribute to improving the current situation," said Richard Eberly, Chembio's President and Chief Executive Officer. "I am proud of the resiliency and dedication of our team over the past months. We are excited about the opportunities ahead of us."
Kingstone Companies reports Q2 operating EPS 23c, consensus 22c » 16:1808/0608/06/20
Reports direct written…
Reports direct written premiums from personal lines grew by 9.1%; Direct written premiums, including commercial liability lines in run off, decreased by 4.8%. Net premiums earned from personal lines decreased by 4.9%; Net premiums earned, including commercial liability lines in run off, decreased 14.6% to $26.6M. Net loss ratio, excluding commercial liability lines in run off1, of 47.1% compared to 50.5%; Net loss ratio, including commercial liability lines in run off, of 48.1% compared to 56.6%. Net combined ratio of 87.3% compared to 94.1%.
Pacira reports preliminary July sales of Exparel of $38.1M » 08:1008/0608/06/20
Pacira reported preliminary unaudited net product sales of Exparel and iovera of $38.1M and $0.8M, respectively, for the month of July 2020. "Given the rapidly changing variables related to the COVID-19 pandemic, the company does not have sufficient visibility to accurately forecast the impact of the pandemic and is currently not providing full-year 2020 financial guidance. In order to provide greater transparency, the company plans to report monthly intra-quarter unaudited net product sales until it has gained sufficient visibility around the impacts of COVID-19," the company said.
Pacira reports Q2 EPS 12c, consensus 9c » 08:0808/0608/06/20
Reports Q2 revenue…
Reports Q2 revenue $75.5M, consensus $72.5M. "We are very pleased to report that since the peak of the impact from COVID-19 in April, we've seen a steady and continued increase in EXPAREL sales. This is a testimony to the resolve of our physician partners who are dedicated to ensuring that patients receive their much-needed surgeries, particularly in the ambulatory setting. This pandemic has accelerated the shift of inpatient procedures to the 23-hour stay environment and we are well positioned to lead the way with our innovative opioid alternatives. Today, we are in a stronger position than ever as we wind down our partnership with DePuy Synthes and take full ownership of the EXPAREL franchise. Our recent financing strengthens our financial foundation and supports our strategy to expand our footprint in non-opioid pain management and regenerative health solutions while simultaneously ramping the top and bottom lines," said Dave Stack, chairman and CEO of Pacira BioSciences.
Pacira announces publication of Phase 4 study of EXPAREL » 07:4208/0508/05/20
Pacira BioSciences announced that full results its Phase 4 study of EXPAREL administered via transversus abdominis plane field block in patients undergoing Cesarean section have been published in Anesthesia and Analgesia. In this study, EXPAREL achieved its primary endpoint with a statistically significant reduction in total postsurgical opioid consumption through 72 hours. EXPAREL also achieved statistical significance for reduction in percentage of opioid-spared patients through 72 hours. This was a multicenter, randomized, double-blind study across 13 clinical sites in the United States, in patients undergoing elective C-section and receiving spinal anesthesia and a multimodal analgesic regimen. Patients were randomized to receive EXPAREL 266 mg plus bupivacaine HCl 50 mg or bupivacaine HCl 50 mg alone administered via TAP field block after delivery. Effectiveness was evaluated in a pre-specified modified intent-to-treat population which met the study criteria regarding proper administration of TAP and multimodal regimen. Key findings include: Significant reduction in total opioid consumption with EXPAREL plus bupivacaine HCl versus bupivacaine HCl. 52% reduction through 72 hours, the primary endpoint of the study. 49% reduction at one week. 41% reduction of opioid consumption at two weeks, although results did not reach statistical significance. Significantly higher percentage of opioid-spared patients with EXPAREL versus bupivacaine HCl, defined as patients who took no more than one oxycodone 10 mg tablet with no opioid-related side effects through 72 hours. Percentage of opioid-spared patients was 2.2 times higher in the EXPAREL group vs bupivacaine HCl group. Optimized pain control through 72 hours, which was comparable in both groups. Patients in the EXPAREL arm of this study were administered a TAP field block with 10 mL EXPAREL admixed with 10 mL 0.25% bupivacaine HCl and 10 mL normal sterile saline injected bilaterally. Patients in the active comparator arm received a TAP field block with 10 mL 0.25% bupivacaine HCl admixed with 20 mL normal sterile saline injected bilaterally. Research shows nearly nine in 10 mothers and mothers-to-be have concerns about taking opioids during and after childbirth, yet 51% of all C-section patients are prescribed an opioid to manage postsurgical pain. Prior to C-section, all patients in this study received an intrathecal injection of 150 mcg preservative-free morphine for spinal injection in conjunction with single-shot spinal anesthesia using 1.4-1.6 mL bupivacaine HCl 0.75% and 15 mcg fentanyl. Following C-section, patients also received an opioid-sparing multimodal analgesic regimen which consisted of 15 mg of intravenous ketorolac, 1000 mg of IV acetaminophen at the time of skin incision closure, and scheduled oral acetaminophen and ibuprofen beginning 6 hours after skin incision closure for up to 72 hours following surgery. Rescue medication was available upon request and postsurgical opioid consumption was collected. Safety was comparable between study groups, with 64 percent of patients in the EXPAREL group experiencing a treatment-emergent adverse event versus 56 percent of patients in the bupivacaine HCl group. The most common TEAEs include pruritus and nausea; serious TEAEs were rare. There were no fatal TEAEs. Earlier this year, Pacira announced positive topline results for CHOICE, a next-generation C-section trial designed to eliminate the use of spinal morphine in the EXPAREL arm. In the study, EXPAREL achieved its primary endpoint with a statistically significant reduction in total opioid consumption while maintaining pain scores through 72 hours, and demonstrated statistical significance for the key secondary endpoint of a reduction in the incidence and severity of itching for 72 hours after surgery.
Parsons backs FY20 revenue view $3.95B-$4.05B, consensus $4.02B 06:4708/0508/05/20